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Abstract— Natural products have played a dominant role in 
the discovery of leads for the development of drugs aimed at 
the treatment of human diseases. Moreover, they may serve as 
lead compounds for the synthesis of potential therapeutic 
agents against several diseases. In this study, we present an 
integrated approach towards the evaluation of the 
antiamyloidogenic activity of isolated components from the 
stigmas of saffron, combining isolation of bioactive components 
from saffron, real-time in vitro screening for noncovalent 
association with Aβ by ESI MS and cell viability assays. This is 
a suitable approach for selecting compounds for the ensuing in 
vivo studies, and it may provide insights into the design and 
synthesis of novel compounds for the prevention, or treatment 
of Alzheimer’s Disease (AD).  
Keywords: Natural products, Alzheimer’s Disease, beta 
amyloid peptide, electrospray tandem mass spectrometry  
I. INTRODUCTION
Natural products have played a dominant role in the 
discovery of leads for the development of drugs aimed at the 
treatment of human diseases. In addition, Mother Nature has 
provided an inspiration to organic and medicinal chemists to 
devise ingenious syntheses that are structural mimics of 
natural compounds, which may serve as potential therapeutic 
agents against several diseases, such as cancer and 
neurodegenerative diseases. Neurodegenerative diseases are 
progressive diseases that produce important health-related 
direct and indirect cost to the world. Alzheimer’s disease 
(AD) is the most common cause of senile dementia in our 
ageing society, and it is characterized by a gradual and 
harmful decline in cognitive and non-cognitive function. AD 
is the fourth main cause of death affecting more than 35 
million people worldwide whereas it is projected to almost 
quadruple by 2050 [1]. Deaths from AD have increased 68 
percent between 2000 and 2010, while those from other 
major diseases, including heart disease, stroke and HIV 
continue to experience significant declines. In addition to the 
human suffering caused by the disease, AD is creating an 
enormous strain on the health care system, families and the 
country’s budget.  
The direct and indirect economic cost associated with the 
disease in 2010 was estimated at more than $600 billion 
worldwide [2]. Estimated costs include direct medical care 
and social support costs, as well as indirect costs, such as 
home-based long-term care services, and the value of lost 
economic productivity in AD patients. The prevalence of 
dementia increases strongly with age and it is projected that 
the costs of dementia could more than double by 2040 as the 
nation's population continues to grow older, assuming that 
the age-specific occurrence rate of the disease remains 
constant [2]. The constantly rising cost of caring for people 
with AD and other dementias has emphasized the immediate 
need to halt and reverse this trend.  
The pathogenesis of AD has not yet been clarified and 
the understanding of the disease mechanism remains elusive. 
Nevertheless, it is widely believed that abnormal 
accumulation and aggregation of disease-specific proteins 
lead to neurodegeneration. It has been proposed that the beta 
amyloid peptide (Aβ), abnormal tau protein or probably both 
play critical role in the development of the disease. In 
particular, abnormal accumulation and aggregation of the Aβ 
peptide lead to the formation and cerebral deposition of 
amyloid plaques, whereas aggregation of hyper-
phosphorylated tau protein results in neurofibrillary tangles 
(NFTs). These senile plaques and neurofibrillary tangles 
have been recognized as the two main pathological hallmarks 
of AD. These changes are also associated with increased 
levels of oxidative stress, inflammation, and nerve cell death 
[3]. Even though the correlation between protein aggregation 
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and nervous system degeneration is mostly unknown, these 
disease-specific aggregated proteins and peptides have 
apparent diagnostic and even therapeutic implications [4]. 
Despite the immense research efforts that have been put over 
the past years on the characterization of AD and the 
development of disease-modifying therapeutic approaches, 
there is still no cure for AD. Moreover, initiation of AD 
pathology is estimated to start several (10-15) years prior to 
the onset of clinical symptoms; thus, making imperative the 
discovery of diagnostic markers for AD [5] as the early 
symptoms of AD are rather subtle.  
The major proteinaceous component found in post 
mortem analyzed plaques is the Aβ peptide, mainly in the 
Aβ1-40 and Aβ1-42 forms, which is a cleavage product of 
the precursor protein, Amyloid Precursor Protein (APP). In 
the process of amyloidosis, the Aβ peptide misfolds and 
aggregates to form an initial nucleus, comprising of a small 
number of Aβ molecules, followed by a rapid elongation 
stage after which incorporates new Aβ molecules. The 
presumed central role of the amyloid plaques in AD 
pathogenesis led to the development of the amyloid cascade 
hypothesis [6]. In fact, Aβ oligomers can either lead to 
neuronal death caused by the toxicity of insoluble amyloid 
fibrils [6], and/or disruption of synaptic function and 
memory failure caused by small soluble Aβ oligomers [7]. 
Among the proposed underlying mechanisms to justify Αβ’s 
neurotoxicity, oxidative stress and neuroinflammation have 
been credited as the principal pathways of neurodegeneration 
[8,9]. In view of the suggested mechanistic link between 
oxidative stress, inflammation and neurodegeneration [10], 
neuroprotection by plant-derived and dietary antioxidants 
may offer a motivating therapeutic route for protection 
against the risk of AD [11-13]. In particular, plants from the 
Mediterranean basin (a global biodiversity “hot-spot” [14], in 
which only the Southern part of Greece offers 6,000 plants 
species and 1,200 endemic [15]) are worth to be investigated.  
In this study, we present an integrated approach towards 
the evaluation of the antiamyloidogenic activity of isolated 
components from the stigmas of saffron (Crocus sativus L.), 
which could lead to novel aggregation inhibitors for the 
prevention, or treatment of AD. Numerous health-promoting 
properties of saffron have been reported such as 
antidepressant [16,17], anti-inflammatory [18], 
antiproliferative action towards specific cancer cell-lines 
[19,20], and reducing blood pressure effects [21]. We 
employed novel nano electrospray ionization (ESI) mass 
spectrometry (MS)-based methodologies to assess the 
noncovalent interactions between the Aβ peptide and natural 
products derived from Crocus sativus L. ESI MS (developed 
by John Fenn; 2002 Nobel prize in Chemistry) is an ideal 
method to elucidate macromolecular structures and study 
their interactions with small molecules or other 
macromolecules [22]. That, in turn, may shed some light 
towards understanding their biological function and 
developing new therapeutics [23]. ESI MS was used for the 
screening of several bioactive compounds in terms of 
binding to Aβ, by noncovalent interactions, and the study of 
their relative binding strength. This in vitro screening was 
complemented with cell viability assays using differentiated 
neuronal SH-SY5Y cells to assess any potential toxic effects 
of the selected substances. The detection of the noncovalent 
interactions between the Aβ peptide and the natural 
product/ligand could provide some insights into the 
mechanisms of AD pathology, as well as the identification of 
potential anti-amyloidogenic agents that can be employed 
towards prevention or even treatment of AD.  
II. MATERIALS AND METHODS
A. Sample Preparation for ESI MS Screening
An aliquot of a freshly prepared Aβ (1-40) 50 µΜ
solution (average Mr 4329.9; Bachem AG, Bubendorf, 
Switzerland) in deionized water was mixed with equimolar 
aqueous solution of the ligand (50 µΜ). Oleuropein (OE) 
(Mr monoisotopic: 540.18) was isolated from olive leaves of 
Olea europaea (var. koroneiki), according to a previously 
described procedure [24], and was generously donated from 
Professor Skaltsounis Laboratory, School of Pharmacy, 
National and Kapodistrian University of Athens. The purity 
was checked by HPLC and NMR and was greater than 99%. 
Major biologically active components of Crocus sativus L. 
were extracted, separated and isolated from dried stigmas of 
saffron flowers provided by Cooperative De Safran Krokos 
(Kozani, Greece) by semi-preparative HPLC as previously 
described [25]. Mass spectral analysis was carried out on a 
Waters Premier quadrupole reflectron time-of-flight 
(QqTOF) instrument equipped with an ESI source in the 
positive ion mode. Accurate mass measurements of the 
crocus-derived bioactive components was performed on-line 
on the QqTOF high-resolution MS using the leukine-
enkephaline standard as a lock mass. Structure 
characterization of the crocus-isolated components was 
carried out by ESI MS in combination with low-energy 
CID/tandem MS of the sodiated [M+Na]+ molecular ions on 
the QqTOF and/or a Bruker 3D-ion trap (MSn, n= 2,3) 
instrument as previously described [25].  
B. Cell Viability Assays
To assess the effects of the selected substances on
neuronal cells, the human neuroblastoma derived SH-SY5Y 
cell line was selected. In vitro viability assays of the 
compounds of interest were performed using the 
differentiated neuronal SH-SY5Y cells to determine any 
potential toxic effects of the selected substances. Upon 
differentiation to neurons, following 6-day exposure to 
10µM retinoic acid, they were treated with a range of 
different concentrations (1 µΜ to 1mM) of each selected 
substance. Different incubation times were assessed for each 
concentration (24, 48 and 72 hours). Since the selected 
substances were dissolved in DMSO, and given its potential 
effect on cell viability, all measurements were normalized to 
those of differentiated SH-SY5Y cells exposed for the same 
time period to the same concentrations of DMSO, in the 
absence of a test substance. The successful differentiation to 
neurons was confirmed by western blotting and 
immunofluorescence using antibodies against the neuronal 
markers MAP2, TUJ1 and NEUN. The effect of the selected 
substances on differentiated SH-SY5Y cell viability was 
assessed using the WST-1 assay. For statistical purposes all 
samples were performed in biological triplicates.  
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III. RESULTS AND DISCUSSION
A. Extraction, Isolation, Scale up Process and Structure
Determination Steps
Chemical analysis of Crocus sativus L. stigmas has
shown the presence of unusually polar carotenoids (crocins), 
picrocrocin and safranal. In the characterization procedure of 
the crocus-derived active components, we have used dried 
stigmas of saffron flowers exhibiting a moisture level of 10-
12 %. Extraction of stigmas has been conducted simply by 
stirring dried herb (50 mg) with 10 mL CH3OH/H2O (50%, 
v/v), at ambient temperature in the dark for 24 h, as 
previously reported [25]. The extracts have been analyzed 
and quantitated by high performance liquid chromatography 
(HPLC) on a C8 reversed phase column (3µm, 150 mm x 2.1 
mm) employing a gradient elution program of acetonitrile
and 0.05 % aqueous TFA. Saffron contains a range of water-
soluble carotenoids, the so-called crocins that are glucosyl
esters of crocetin. The crocins of the crude extract have been
separated and isolated by semi-preparative HPLC and
Centrifugation Partition Chromatography (CPC). The semi-
preparative HPLC system was equipped with a C18 reversed
phase column and the isolation of crocins was carried out
with a gradient elution program of H2O/acetonitrile, whereas
detection of the eluted crocin components was performed at
the wavelengths of 250, 325 and 440  nm. Alternatively, CPC
and/or Accelerated Solvent Extraction (ASE) was also
employed to purify the major and some of the minor crocins
on a preparative scale since large amounts of the pure
compounds (crocins) are required in order to evaluate the
pharmacological activities. The purity of all isolated crocus-
derived compounds prior to scale up process has been
checked by both high-resolution MS and NMR analysis.
Generally, crocins are glycosyl esters of crocetin a water-
soluble carotenoid dicarboxylic acid. Crocetin mainly occurs 
in all-trans form however the cis-isomers have been also 
identified. Likewise, crocins could be divided according to 
the number and the position of the β-L-glucopyranosides 
attached to the central carotenoid unit, comprising crocetin 
mono- and bis-ester glycoside compounds with R1 and R2 
substituents being mono- (G), bi- (GB) and tri-saccharide 
(GT and NP) moieties [25] (Figure 1). For the structural 
elucidation of glycosylated crocetins (i.e., crocins) from the 
stigmas of saffron (Crocus sativus L.) six derivatives 
containing one up to five glucosyl residues with maximum 
number of three glucoses per glycosylation site (glucose, 
gentiobiose, gentiotriose and neapolitanose) were isolated 
and purified by semi-preparative HPLC.  
Figure 1. Chemical structures of selected crocin ester glycosides 
isolated from the stigmas of Crocus sativus L. The variable 
substituents R1 and R2 on the crocetin refer to the mono-, bi- and tri-
saccharide moieties G, GB, GT and NP. 
The major Crocus sativus L.-derived bioactive constituents 
are crocetin mono- and bis-ester glycoside compounds, 
containing mono- and bi-saccharides (crocins). ESI MS was 
employed in combination with low-energy CID/tandem MS 
of the sodiated [M+Na]+ crocin precursor ions utilizing the 
QqTOF MS and/or a 3D-ion trap (MSn, n= 2,3) instrument 
[25]. This work enabled the structural elucidation of the 
aforementioned glycoconjugates by multi-stage MS and 
focused on the identification of new crocins in saffron with 
special emphasis on the differentiation of positional crocetin 
glycoside isomers. The latter was especially important in 
distinguishing between the two different penta-glucosylated 
crocetins containing the isomeric trisaccharides gentiotriose 
(GT) and neapolitanose (NP) by CID-MS3 analysis.  
B. ESI MS Screening Experiments
The formation of 1:1 noncovalent complexes of Aβ with 
certain antioxidants such as oleuropein (OE) and melatonin 
(M) has been previously demonstrated by ESI MS [26,27],
whereas their interaction with the hydrophobic region of the
peptide has been reported by ESI MS mapping studies [28].
Similar 1:1 noncovalent interactions between the Aβ peptide
and the main crocus components were also observed in this
study, as shown in the deconvoluted ESI mass spectrum of
Aβ and the bi-saccharide containing crocin TC2 (Figure 2).
Nevertheless, it should be noted that the observation of these
noncovalent interactions was only possible only after careful
optimization of the experimental parameters especially in
terms of the entrance potential in the MS ion source, the
ligand concentration, the pH and the presence of organic
modifiers in the solution, which affect conformational
changes of the Aβ peptide.
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Figure 2. The deconvoluted ESI mass spectrum of the Aβ–TC2 
noncovalent complex acquired on a QqTOF mass spectrometer.  
The noncovalent complexes of Aβ with OE and crocins 
showed considerable stability even under experimental 
conditions, which usually do not favor noncovalent 
interactions, e.g., high organic modifier content and elevated 
entrance potential. The specificity of these noncovalent 
interactions was also evaluated at low concentration levels, 
i.e., 5-100 µΜ, where the occurrence of nonspecific
aggregation in the gas-phase can be prevented. For example,
the ESI signals corresponding to the noncovalent complex of
Aβ with OE and crocins were present for all concentration
levels, thus indicating a very specific interaction. On the
contrary, ESI MS analysis of the Aβ – quercetin glycoside
solution yielded no signals corresponding to the formation of
a noncovalent complex [13]; thus showing the specificity of
the interactions of the Aβ peptide with OE, M and the
Crocus sativus L.- derived components.
In another study, the binding strength of the 
aforementioned interactions was assessed by conducting ESI 
tandem MS experiments. In this study the +5 charged ion of 
the noncovalent complex was selected and subjected to 
collision-induced dissociation in the QqTOF mass 
spectrometer. It was clearly shown that it takes more energy 
to dissociate the Aβ signal with OE and crocins than that of 
the Aβ with M and trans-crocetin, thus demonstrating the 
higher binding strength of the former noncovalent 
interactions over the latter.  
C. Cell Viability Assays
At the cellular level, OE and trans-crocetin did not
appear to have a toxic effect at concentrations up to 10µM. 
Similar results were obtained at both 24 and 72 hours of 
incubation with each substance. It should be noted that trans-
crocetin appear to modestly enhance cell proliferation at 24 
hours of incubation with concentrations between 0.1 and 10 
µM. Cell viability appears to be compromised for higher 
concentrations, especially during prolonged incubation time 
as shown for trans-crocetin (Figure 3).  
Figure 3. Percent viability of differentiated SH-SY5Y cells 
following exposure to different concentrations of trans-crocetin. 
Since trans-crocetin is diluted in DMSO the measurements were 
normalized to the viability of differentiated SH-SY5Y cells exposed 
to the same concentration of DMSO alone.  
Following these preliminary cell viability studies, PC12 
cells producing hyper-phosphorylated tau along with PC12 
wild type will be exposed to different concentrations of the 
selected compounds and cell proliferation/viability assays 
will be performed. Thus in vitro scanning of the compounds 
of interest towards the inhibition of APP misprocessing and 
Aβ generation, as well as the abnormal tau hyper-
phosphorylation will be performed. Therefore, the potential 
inhibitory role of the crocus-isolated compounds on Aβ 
production and key molecules of APP misprocessing (e.g., 
C99, sAPPβ), as well as enzymes that regulate APP 
sequential cleavage (e.g., BACE-1, presenilin and nicastrin) 
and tau hyper-phosphorylation will be monitored.  
IV. CONCLUSION
This work demonstrates that natural products may be 
effective in inhibiting Aβ fibrillogenesis without limiting 
neuronal cell viability at low concentrations. This integrated 
strategy combining isolation of bioactive components from 
saffron, real-time in vitro screening for noncovalent 
association with Aβ by ESI MS and cell viability assays is a 
suitable approach for selecting compounds for the ensuing in 
vivo studies. In addition, this methodology may shed some 
light into the AD pathogenesis. Finally, these results may 
provide insights into the design and synthesis of novel 
compounds, which could act as protective or even 
therapeutic agents against AD. These natural products and 
derivatives thereof can be eventually exploited, in the form 
of nutraceuticals towards the prevention and/or treatment of 
AD. The potential use of nutraceuticals will also have a 
positive impact to preserve and enhance the environment and 
natural resources, and it will provide a stimulus for extensive 
cultivation of some of these plants in the originating 
countries.  
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